+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P07366(IGFBP4 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P07366(IGFBP4 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

Insulin-like growth factor-binding protein 4 (IGFBP4) is a member of the IGFBP family that regulates the bioavailability and activity of insulin-like growth factors (IGFs), particularly IGF-1 and IGF-2. by modulating their interaction with IGF receptors. IGFBP4 acts as a critical mediator in cellular growth, differentiation, and metabolism. It binds IGFs with high affinity, sequestering them in circulation and limiting their access to target tissues. Additionally, IGFBP4 can exert IGF-independent effects on cell proliferation and apoptosis through interactions with other proteins or cell-surface receptors.

Antibodies targeting IGFBP4 are essential tools for studying its expression, localization, and function in physiological and pathological contexts. They are widely used in techniques such as Western blotting, immunohistochemistry (IHC), and enzyme-linked immunosorbent assays (ELISA) to quantify IGFBP4 levels in tissues or biological fluids. Dysregulation of IGFBP4 has been implicated in various diseases, including cancers (e.g., breast, prostate, colorectal), cardiovascular disorders, and metabolic syndromes. For instance, IGFBP4 overexpression or cleavage by pregnancy-associated plasma protein-A (PAPP-A) may influence tumor progression or angiogenesis. Researchers also utilize IGFBP4 antibodies to explore its role in developmental processes, aging, and tissue repair. These antibodies aid in deciphering IGFBP4's dual role as both an inhibitor and potentiator of IGF signaling, depending on cellular context and post-translational modifications. Such studies contribute to potential therapeutic strategies targeting the IGF axis.